The Leucegene project aims at paving the way for a new era in personalized medicine for patients suffering from acute myeloid leukemia (AML). The current sample cohort consists of 529 primary samples acquired and managed by the BCLQ among which 452 are AML samples with 373 samples classified as diagnostic AML samples (excluding acute promyelocytic leukemia(APL)).
To cite Leucegene:
Leucegene's team requests that authors who use Leucegene data for publication acknowledge it in the acknowledgment section.

Example: The results/or Some of the results obtained in this publication are based upon data generated by the Leucegene group primarily located at IRIC in Montreal, Canada and supported by Genome Canada and Genome Qu├ębec. This data was made possible through human AML specimens provided by the BCLQ, Montreal, Canada.

To cite a Leucegene tool:
Please follow the instructions provided by each specific tool.

To access Leucegene data:
Leucegene transcriptomic data was deposited in the Gene Expression Omnibus (GEO) :